Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 78, Issue 3, Pages S53-S62Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2017.12.019
Keywords
atopic dermatitis; baricitinib; eczema; JAK inhibitor; ruxolitinib; systemic therapy; tofacitinib.
Categories
Funding
- Bayer
- LEO Pharma
- Sanofi
Ask authors/readers for more resources
The Janus kinas-signal transducer and activator of transcription pathway is a conserved master regulator of immunity and myeloproliferation. Advanced understanding of this pathway has led to development of targeted inhibitors of Janus kinases (Jakinibs). As a class, JAK inhibitors effectively treat a multitude of hematologic and inflammatory diseases. Given such success, use of JAK inhibitors for mitigation of atopic dermatitis is under active investigation. Herein, we review the evolving data on the safety and efficacy of JAK inhibitors in treatment of atopic dermatitis. Although it is still early in the study of JAK inhibitors for atopic dermatitis, evidence identifies JAK inhibitors as effective alternatives to conventional therapies. Nonetheless, multiple large safety and efficacy trials are needed before widespread use of JAK inhibitors can be advocated for atopic dermatitis. (J Am Acad Dermatol 2018; 78: S53-62.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available